Clinical Scorecard: Distinct Microglial Profiles Identified in Epigenomic Subtypes of Late-Onset Alzheimer’s Disease
At a Glance
Category
Detail
Condition
Late-onset Alzheimer’s disease (LOAD), a common dementia characterized by amyloid-beta plaques and neurofibrillary tangles leading to neuronal loss
Key Mechanisms
Heterogeneous molecular subtypes identified via epigenomic (DNA methylation) and transcriptomic profiling revealing distinct pathways including immune activation, protein metabolism, and synaptic dysfunction
Target Population
Individuals aged 65 and older diagnosed with LOAD
Care Setting
Neurological and dementia research centers with access to postmortem brain tissue and molecular diagnostic tools
Key Highlights
LOAD exhibits significant heterogeneity in onset, progression, symptoms, and treatment response linked to distinct molecular subtypes.
Epigenomic profiling using genome-wide DNA methylation data from multiple cohorts identified reproducible LOAD subtypes with unique microglial and molecular signatures.
Lifestyle factors such as physical inactivity and low education correlate with methylation profiles predictive of dementia onset, highlighting modifiable risk components.
Guideline-Based Recommendations
Diagnosis
Use clinical criteria including MMSE <24 or CDR ≥1 combined with neuropathological assessment (CERAD neuritic plaque score and Braak NFT stage) for LOAD diagnosis.
Exclude co-pathologies such as argyrophilic grain disease, alpha-synuclein, and TDP-43 pathologies to refine diagnosis.
Incorporate epigenomic and transcriptomic molecular profiling to identify LOAD subtypes and understand disease heterogeneity.
Management
Consider modifiable lifestyle factors (e.g., physical activity) as potential interventions to delay dementia onset.
Tailor therapeutic approaches based on molecular subtype characterization to address distinct pathogenic mechanisms.
Monitoring & Follow-up
Monitor cognitive function using standardized tools (MMSE, CDR) alongside molecular biomarkers where available.
Track epigenetic and transcriptomic markers longitudinally to assess disease progression and subtype stability.
Risks
Recognize that heterogeneity in molecular subtypes may influence disease progression and treatment response.
Account for environmental and lifestyle factors impacting epigenetic modifications contributing to LOAD risk.
Patient & Prescribing Data
Older adults (>65 years) diagnosed with late-onset Alzheimer’s disease
Molecular subtype identification via epigenomic profiling may guide personalized therapeutic strategies; lifestyle modifications remain important adjunctive measures.
Clinical Best Practices
Employ rigorous clinical and neuropathological criteria to confirm LOAD diagnosis and exclude confounding pathologies.
Utilize genome-wide DNA methylation profiling to identify epigenomic subtypes and understand underlying biological heterogeneity.
Incorporate multi-omics data integration (proteomics, transcriptomics) to refine subtype classification and therapeutic targeting.
by Valentin T. Laroche, Rachel Cavill, Morteza Kouhsar, Joshua Müller, Rick A. Reijnders, Joshua Harvey, Adam R. Smith, Jennifer Imm, Jarno Koetsier, Luke Weymouth, Lachlan MacBean, Giulia Pegoraro, Lars Eijssen, Byron Creese, Gunter Kenis, Betty M. Tijms, Daniel van den Hove, Katie Lunnon, Ehsan Pishva
